Skip to main content
Premium Trial:

Request an Annual Quote

Another Player Joins the Fray

Is there room for another personal genomics company? That's the question Daniel MacArthur asks on the news that Australia-based Lumigenix recently launched and will offer its genetic test for $470, slightly more than competitor 23andMe. The biggest obstacles, he writes, are its second-to-market status and the anti-genetic testing climate in Australia. While some experts are optimistic that in the future consumer choice will be favored, MacArthur thinks it's a wait-and-see game. "It remains to be seen whether this venture will succeed in the face of rigorous competition, over-zealous regulation, and an economic slowdown that will likely seriously punish sales of 'luxury' goods like genome scans -- but I'd say the odds aren't good."

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.